Emerging Treatments

A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. Hou J et al. Am J Clin Oncol. 2017 Sep 19. doi: 10.1097/COC.0000000000000404. [Epub ahead of print]. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Cavenagh J et al. Br J Cancer. 2017 Sep…

Details

Diagnostic techniques and prognostic indicators

Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Bhutani M et al. Lancet Haematol. 2017 Sep;4(9):e443-e451. doi: 10.1016/S2352-3026(17)30143-6. Detection of Circulating Plasma Cells in Multiple Myeloma. Alix-Panabières C et al. Clin Chem. 2017 Sep 18. pii: clinchem.2017.275446. doi: 10.1373/clinchem.2017.275446. [Epub ahead of print]. Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. Sachpekidis C et al. Am J Nucl Med Mol Imaging. 2017 Sep…

Details

Current treatments

Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group. Waszczuk-Gajda A et al. J Clin Apher. 2017 Sep 18. doi: 10.1002/jca.21584. [Epub ahead of print]. Autologous hematopoietic cell transplantation for multiple myelomapatients with renal insufficiency: a center for international blood and marrow transplant research analysis. Mahindra A et al. Bone Marrow Transplant. 2017 Sep 18. doi: 10.1038/bmt.2017.198. [Epub…

Details

Complications of myeloma and its treatments

Plasma Cell Infiltration of the Kidney as a Manifestation of Myeloma: A Report of Three Cases. Kaur T et al. Indian J Nephrol. 2017 Sep-Oct;27(5):395-398. doi: 10.4103/ijn.IJN_215_16. Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures. Crowley MP et al. Pathol Oncol Res. 2017 Sep 13. doi: 10.1007/s12253-017-0300-9. [Epub ahead of print]. Multiple Myeloma Presenting as Massive Amyloid Deposition in a Parathyroid…

Details

Biology and genetics

Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis. Wang S et al. Cell Death Dis. 2017 Sep 21;8(9):e3058. doi: 10.1038/cddis.2017.450. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. Mroczek S et al. Nat Commun. 2017 Sep 20;8(1):619. doi: 10.1038/s41467-017-00578-5. Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase. Dorasamy MS et al. J…

Details

IMWG study demonstrates benefit of whole body CT imaging in myeloma patients

A recent study, conducted by the International Myeloma Working Group (IMWG), has demonstrated the benefits of whole body computed tomography (WBCT) compared to conventional skeletal survey (CSS) for identifying osteolytic lesions in myeloma. The study, published in Blood Cancer Journal, found that WBCT is more sensitive than CSS in detecting skeletal lesions, with 20-25% patients…

Details

Myeloma UK funded research demonstrates impact of neutral tumour evolution on myeloma patient outcome

A study, funded by Myeloma UK, has demonstrated that neutral tumour evolution in myeloma is associated with poorer prognosis. Neutral evolution is the term used to describe evolution caused by random genetic mutations and are normally considered to be neither beneficial nor detrimental to survival. However, in this study, such tumours conferred a worse prognosis…

Details

Supportive treatments

Oncological and functional results of the surgical treatment of vertebral metastases in patients with multiple myeloma. Guzik G et al. BMC Surg. 2017 Aug 23;17(1):92. doi: 10.1186/s12893-017-0288-9. Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports. Lum EL et al. Transplant Direct. 2017 Jul 21;3(8):e200. doi: 10.1097/TXD.0000000000000716. eCollection 2017 Aug. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Lee OL et al. Intern Med…

Details

Related conditions

18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Albano D et al. Eur J Nucl Med Mol Imaging. 2017 Aug 19. doi: 10.1007/s00259-017-3810-5. [Epub ahead of print]. Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: a case series. Cantone E et al. J Med Case Rep. 2017 Aug 10;11(1):219. doi: 10.1186/s13256-017-1382-4. POEMS syndrome in a…

Details

General

Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach. Baertsch MA et al. Hematol Oncol. 2017 Aug 25. doi: 10.1002/hon.2473. [Epub ahead of print]. Evolutionary biology of high-risk multiple myeloma. Pawlyn C et al. Nat Rev Cancer. 2017 Aug 24;17(9):543-556. doi: 10.1038/nrc.2017.63. Comprehensive Evaluation of the Revised International Staging System in Multiple Myeloma Patients…

Details